Morgan Stanley stock (NYSE: MS) slips 2% into the weekend as Fed week looms
24 January 2026
1 min read

Morgan Stanley stock (NYSE: MS) slips 2% into the weekend as Fed week looms

New York, January 23, 2026, 20:13 EST — Market closed

  • Morgan Stanley shares dropped 2.2% on Friday, closing at $179
  • Wall Street enters a busy week, eyeing the Fed decision alongside major earnings reports
  • SpaceX’s IPO lead-bank discussions and new analyst price targets are fueling buzz around upcoming deals

Morgan Stanley (MS.N) shares dropped 2.2%, closing at $179 on Friday, capping off a turbulent week for U.S. stocks before the weekend.

This shift is crucial as the upcoming sessions will put two key factors to the test—interest rate levels and whether investors stay active or pull back from trading, both of which typically drive sharp moves in brokerage stocks.

The first Fed meeting of the year kicks off the week, alongside a wave of major tech earnings and ongoing geopolitical tensions that have had investors jittery, swinging in and out of risk assets in rapid succession. 1

On Friday, the Dow dropped 0.58%, the S&P 500 ended close to unchanged, and the Nasdaq gained 0.28%, despite Intel’s shares sliding on a gloomy forecast. “We feel pretty good about where we are today,” said Jason Blackwell, chief investment strategist at Focus Partners Wealth. 2

Morgan Stanley tumbled, tracking declines at other major banks. Goldman Sachs lost 3.7%, while JPMorgan Chase slipped roughly 2%.

Morgan Stanley is reportedly one of four Wall Street banks in the running for senior roles on SpaceX’s possible IPO, according to a source familiar with the situation who spoke to Reuters. The banks did not comment, and SpaceX has yet to respond to requests for comment. 3

Analysts haven’t been quiet either. Bank of America stuck with a buy rating on Morgan Stanley, boosting its price target to $220. They said “the blueprint is in place,” according to 8 .

Morgan Stanley’s latest quarter remains a key reference point for investors. The bank posted $17.9 billion in net revenues and $2.68 earnings per diluted share for Q4. CEO Ted Pick called the year’s results “outstanding,” highlighting a year-end total of $9.3 trillion in client assets across Wealth and Investment Management. 4

The Federal Reserve’s rate-setting Federal Open Market Committee will meet next on Jan. 27–28, marking the next key macro event. 5

Strategists describe the market as unsettled after a week marked by sharp swings. “It’s been a short but steep roller-coaster ride,” said Yung-Yu Ma of PNC Financial Services. Franklin Templeton’s Chris Galipeau pointed to earnings as the main factor, noting investors are grappling with high valuations. Oxford Economics’ Michael Pearce expects the Fed to “take an extended pause.” 6

Morgan Stanley bulls face a clear risk: any renewed spike in trade tensions or a Fed signal more hawkish than anticipated could weigh on stocks, stall deals, and squeeze brokers once more. The next major event arrives Wednesday, with the Fed’s policy decision due at 2:00 p.m. ET, followed by Chair Jerome Powell’s press conference at 2:30 p.m. ET. 7

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Shopify (SHOP) stock price ends flat after layoffs report — what to watch before Monday’s open
Previous Story

Shopify (SHOP) stock price ends flat after layoffs report — what to watch before Monday’s open

JNJ stock closes at $220 after analyst target hikes — what could move Johnson & Johnson next week
Next Story

JNJ stock closes at $220 after analyst target hikes — what could move Johnson & Johnson next week

Go toTop